missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. 18028167

LIGHT/TNFSF14 Antibody (MM0456-8C34), DyLight 550, Novus Biologicals™

Mouse Monoclonal Antibody

Brand:  Novus Biologicals NBP2-11964R

Product Code. 18028167

  • 642.00€ / 0.10mL

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

LIGHT/TNFSF14 Monoclonal specifically detects LIGHT/TNFSF14 in Human samples. It is validated for Flow Cytometry.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

LIGHT/TNFSF14
Monoclonal
DyLight 550
50mM Sodium Borate with 0.05% Sodium Azide
TNFSF14
Human recombinant LIGHT/TNFSF14 (extracellular domain)
0.1 mL
Primary
Human
Purified
Flow Cytometry
MM0456-8C34
Flow Cytometry
CD258, CD258 antigen, delta transmembrane LIGHT, Herpes virus entry mediator ligand, Herpesvirus entry mediator ligand, HVEM-L, HVEMLherpesvirus entry mediator-ligand, ligand for herpesvirus entry mediator, LIGHTherpesvirus entry mediator A, LTg, TR2, tumor necrosis factor (ligand) superfamily, member 14, tumor necrosis factor ligand superfamily member 14, tumor necrosis factor receptor-like 2, tumor necrosis factor superfamily member LIGHT
Mouse
Protein G purified
Apoptosis
8740
Store at 4C in the dark.
IgG1
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.